14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CNCE ranks #10579 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Concert Pharmaceuticals Stock Forecast NASDAQ:CNCE

$3.15 (2.94%)

Volume: 38k

Closed: Jan 14, 2022

Hollow Logo Score: -2.033

Concert Pharmaceuticals Stock Forecast

$3.15 (2.94%)

Volume: 38k

Closed: Jan 14, 2022

Score Hollow Logo -2.033

Concert Pharmaceuticals Company Profile

99 Hayden Avenue

Lexington MA 02421



Industry: Biotechnology

Sector: Healthcare

Concert Pharmaceuticals


Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for genetic diseases, inflammatory disease, and neurologic disorders. The company’s clinical-stage product candidates include AVP-786, which is in Phase 2 and Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including Alzheimer’s agitation, depressive disorders, and residual schizophrenia; and CTP-656, which is in Phase I clinical trial to treat cystic fibrosis. It also has completed the Phase 1 clinical trial of CTP-730 for the treatment of inflammation or cancer; and JZP-386 for the treatment of excessive daytime sleepiness and cataplexy. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE